Key points from the evidence. Aclidinium bromide (Eklira Genuair) is an inhaled long-acting muscarinic antagonist (LAMA) for maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).It received a European marketing authorisation in July 2012 and was launched in the UK in September 2012.2012) Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD: Journal of Chronic Obstructive Pulmonary Disease 9: 90–101. Jones PW, Singh D, Bateman ED et al.